|
Bauerschmitz
G, Hüchel S, Gallwas J, Gründker C (2023) Inhibition of increased
invasiveness of breast cancer cells with acquired tamoxifen-resistance
by suppression of CYR61. Cancer Genomics & Proteomics 20(6):531-538
Loris
J, Hanesch L, Bauerschmitz G, Gallwas J, Gründker C (2023) Activation
of G protein-coupled Estrogen Receptor 1 (GPER1) reduces progression of
vulvar carcinoma cells. International Journal of Molecular Sciences 24:13705
Schüler-Toprak
S, Skrzypczak M, Gründker C, Ortmann O, Treeck O (2023) Role of
estrogen receptor β, G-protein coupled estrogen receptor and
estrogen-related receptors in endometrial and ovarian cancer. Cancers 15:2845
Ruckriegl
S, Loris J, Wert K, Bauerschmitz G, Gallwas J, Gründker C (2023)
Knockdown of G protein-coupled estrogen receptor 1 (GPER1) enhances
tumor-supportive properties in cervical carcinoma cells. Cancer
Genomics & Proteomics 20(3):281-297
Schmitz
V, Bauerschmitz G, Gallwas J, Gründker C (2022) Suppression of G
protein-coupled estrogen receptor 1 (GPER1) enhances the anti-invasive
efficacy of selective ERβ agonists. Anticancer Research 42(11):5187-5194
Läsche
M, Gallwas J, Gründker C (2022) Like brothers in arms: How hormonal
stimuli and changes in the metabolism signaling cooperate, leading HPV
Infection to drive the onset of cervical cancer. International Journal
of Molecular Sciences 23(9):5050
Steifensand
F, Gallwas J, Bauerschmitz G, Gründker C (2021) Inhibition of
metabolism as a therapeutic option for tamoxifen-resistant breast
cancer cells. Cells 10(9):2398
Läsche
M, Urban H, Gallwas J, Gründker C (2021) HPV and other microbiota;
who‘s good and who‘s bad: Effects of the microbial environment on the
development of cervical cancer - a non-sytematic review. Cells 10(3):714
Gründker C, Emons G (2021) Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer. Cells 10(2): 437
Emons G, Gründker C (2021) The role of gonadotropin-releasing hormone (GnRH) in endometrial cancer. Cells 10(2):292
Kolb
K, Hellinger J, Kansy M, Wegwitz F, Bauerschmitz G, Emons G, Gründker C
(2020) Influence of ARHGAP29 on invasion of mesenchymal transformed
breast cancer cells. Cells 9(12):2616
Hellinger
JW, Schömel F, Buse JV, Lenz C, Bauerschmitz G, Emons G, Gründker C
(2020) Identification of breast cancer invasion drivers by secretom
analysis: insight into CTGF signaling. Scientific Reports 10(1):17889
Gründker
C, Emons G (2020) Die HPO (Hypothalamus-Hypophyse-Ovar)-Achse -
"revisited". Gynäkologe 53(8):494-501
Läsche
M, Emons G, Gründker C (2020) Shedding new light on cancer
metabolism: A metabolic tightrope between life and death. Frontiers in
Oncology 10:409
Hellinger JW, Hüchel S, Goetz L, Bauerschmitz G, Emons
G, Gründker C (2019) Inhibition of CYR61-S100A4 axis limits breast cancer
invasion. Frontiers in Oncology 9:1074
Gründker C, Wokoun U, Hellriegel M, Emons G (2019)
Inhibition of aerobic glycolysis enhances the anti-tumor efficacy of Zoptarelin
Doxorubicin in triple-negative breast cancer cells. The Journal of
Obsterics and Gynaecology Research 45(7):1334-1342
Gründker C, Läsche M, Hellinger JW, Emons G (2019)
Mechanisms of metastasis and cell mobility: The role of metabolism. Geburtshilfe
und Frauenheilkunde 79:184-188
Girgert
R, Emons G, Gründker C (2019) Estrogen signaling in ERα-negative
breast cancer: ERβ and GPER. Frontiers in Endocrinology 9:781
Girgert R, Emons G, Gründker C
(2018) Inhibition of growth hormone receptor by antagonist Somavert
reduces expression of GPER and prevents growth stimulation of triple-negative
breast cancer by 17β-estradiol. Oncology Letters 15(6):9559-9566
Gründker C, Emons G (2017) The Role of
Gonadotropin-Releasing Hormone in Cancer Cell Proliferation and
Metastasis. Frontiers in Endocrinology 8:187
Wokoun U, Hellriegel M, Emons G, Gründker C
(2017) Co-treatment of breast cancer cells with pharmacologic doses of
2-Deoxy-D-Glucose and Metformin: Starving tumors. Oncology
Reports 37(4):2418-2424
Girgert R, Emons G, Gründker C
(2017) Gefitinib inhibits growth of triple-negative breast cancer
cells in part by reduction of GPER expression, preventing 17β-estradiol induced
cell growth. Oncology Reports 37(2):1212-1218
Gründker C, Bauerschmitz G, Schubert A,
Emons G (2016) Invasion and increased expression of S100A4 and CYR61 in
mesenchymal transformed breast cancer cells is downregulated by
GnRH. International Journal of Oncology 48(6):2713-2721
Gründker C, Bauerschmitz G, Knapp J, Schmidt E,
Olbrich T, Emons G (2015) Inhibition of SDF-1/CXCR4 system-induced
epithelial-mesenchymal transition by kisspeptin-10. Breast Cancer Research
and Treatment 152(1):41-50
Scheerer-Bernhard JU, Tkachenko OY, Heistermann M,
Gründker C, Nayudu PL (2015) Body weight associated differences in ovarian
morphology in the captive common marmoset (Callithrix jacchus). Animal
Reproduction Science 157:44-55
Hinsche O, Girgert R, Emons G, Gründker C (2015)
Estrogen receptor β selective agonists reduce invasiveness of
triple-negative breast cancer cells. International Journal of
Oncology 46:878-884
Girgert R, Emons G, Gründker C (2014) Inhibition of
GPR30 by estriol successfully prevents growth stimulation of triple-negative
breast cancer cells by 17β-estradiol. BMC Cancer 14:935
Ziegler E, Hansen M-T, Haase M, Emons G, Gründker C
(2014) Generation of MCF-7 cells with aggressive metastatic potential in
vitro and in vivo. Breast Cancer Research and Treatment 148(2):269-277
Emons G, Gorchev G, Sehouli J, Wimberger P,
Stähle A, Hanker L, Hilpert F, Sindermann H, Gründker C, Harter P (2014)
Efficacy and safety of AEZS-108 (INN: Zoptarelin doxorubicin acetate) an
LHRH agonist linked to doxorubibin in woman with platinum refractory or
resistant ovarian cancer expressing LHRH receptors: a multicenter phase II
trial of the AGO-study group (AGO GYN 5). Gynecologic
Oncology 133(3):427-432
Schmidt E, Haase M, Ziegler E, Emons G, Gründker
C (2014) Kisspeptin-10 inhibits stromal-derived factor-1-induced invasion
of human endometrial cancer cells. International Journal of Gynecological
Cancer 24(2):210-217
Emons G, Gorchev G, Harter P, Wimberger P, Stähle A,
Hanker L, Hilpert F, Beckmann MW, Dall P, Gründker C, Sindermann H, Sehouli J
(2014) Efficacy and safety of AEZS-108 (LHRH agonist linked to doxorubicin) in
women with advanced or recurrent endometrial cancer expressing LHRH receptors:
a multicenter phase 2 trial (AGO GYN 5). International Journal of Gynecological
Cancer 24(2):260-265
Ziegler E, Olbrich T, Emons G, Gründker C (2013)
Antiproliferative effects of kisspeptin-10 depend on artificial GPR54 (KiSS1R)
expression levels. Oncology Reports 29(2):549-554
Reutter M, Emons G, Gründker C (2013) Starving
tumors: Inhibition of glycolysis reduces viability of human endometrial
and ovarian cancer cells and enhances antitumor efficacy of GnRH
receptor-targeted therapies. International Journal of Gynecological
Cancer 23(1):34-40
Block M, Gründker C, Fister S, Kubin J, Wilkens L,
Mueller MD, Hemmerlein B, Emons G, Günthert AR (2012) Inhibition of the
AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of
gonadotropin-releasing hormone I and II to overcome tamoxifene resistance in
breast cancer cells. International Journal of
Oncology 41:1845-1854
Girgert R, Emons G, Gründker C
(2012) Inactivation of GPR30 reduces growth of triple-negative breast
cancer cells: possible application in targeted therapy. Breast Cancer
Research and Treatment 134:199-205
Gründker C, Ernst J, Reutter M, Ghadimi BM, Emons G
(2011) Effective targeted chemotherapy using AN-152 for LHRH receptor-positive
pancreatic cancers. Oncology Reports 26: 629-635
Föst C, Duwe F, Hellriegel M, Schweyer S, Emons G,
Gründker C (2011) Targeted chemotherapy for triple-negative breast cancers via
LHRH receptor. Oncology Reports 25:1481-1487
Schubert A, Hawighorst T, Emons G, Gründker C (2011)
Agonist and antagonists of GnRH-I and -II reduce metastasis of triple-negative
human breast cancer cells in vivo. Breast Cancer Research and
Treatment 130(3): 783-790
Olbrich T, Ziegler E, Türk G, Schubert A, Emons G,
Gründker C (2010) Kisspeptin-10 inhibits bone-directed migration of
GPR54-positive breast cancer cells: evidence for a dose-window
effect. Gynecologic Oncology 119:571-578
Emons G, Kaufmann M, Gorchev G, Tsekova V, Gründker C,
Günthert AR, Hanker LC, Velikova M, Sindermann H, Engel J, Schally AV (2010)
Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist
linked to doxorubicin, in women with LHRH receptor-positive
tumors. Gynecologic Oncology 119:457-461
Koch M, Hussein F, Woeste A, Gründker C, Frontzek K,
Emons G, Hawighorst T (2011) CD36 mediated activation of endothelial cell
apoptosis by an N-terminal recombinant fragment of thrombospondin-2 inhibits
breast cancer growth and metastasis in vivo. Breast Cancer Research and
Treatment 128(2):337-346
Gründker C, Föst C, Fister S, Nolte N, Günthert AR,
Emons G (2010) GnRH-II antagonist induces apoptosis in MCF-7 and
triple-negative MDA-MB-231 human breast cancer cells in vitro and in
vivo. Breast Cancer Research 12(4):R49
Block M, Fister S, Emons G, Seeber S, Gründker C,
Günthert AR (2010) Antiproliferative effects of antiestrogens and inhibitors of
growth factor receptor signaling on endometrial cancer. Anticancer
Research 30(6):2025-2031
Hawighorst
T, Stein W, Gründker C, Emons G (2010) Angiogenese in Reproduktionsmedizin und
gynäkologischer Onkologie. Gynäkologe 43:595-600
Gründker
C, Hawighorst T, Emons G (2010) Tumorstammzellen in Mamma- und weiblichen
Genitalkarzinomen. Gynäkologe 43:569-573
Girgert R, Hanf V, Emons G, Gründker C (2010) Signal
transduction of the melatonin receptor MT1 is disrupted in breast cancer cells
by electromagnetic fields. Bioelectromagnetics 31(3):237-245
Fister S, Günthert AR, Aicher B, Paulini KW, Emons G,
Gründker C (2009) GnRH-II antagonists induce apoptosis in endometrial, ovarian
and breast cancers via activation of stress-induced MAPKs p38 and JNK and
pro-apoptotic protein Bax. Cancer Research 69:6473-6481
Emons G, Sindermann H, Schally AV, Gründker C (2009)
LHRH receptor targeted chemotherapy using
AN-152. Neuroendocrinology 90(1):15-18
Girgert R, Hanf V, Emons G, Gründker C (2009)
Membrane-bound melatonin receptor MT1 down-regulates estrogen responsive genes
in breast cancer cells. Journal of Pineal Research 47:23-31
Girgert R, Hanf V, Emons G, Gründker C (2009) Exposure
of MCF-7 breast cancer cells to electromagnetic fields up-regulates the
plasminogen-activator system. International Journal of Gynecological
Cancer 19:334-338
Hermann RM, Wolff HA, Jarry H, Thelen P, Gründker C,
Rave-Fraenk M, Schmidberger H, Christiansen H (2008) In vitro studies on the
modification of low-dose hyper-radiosensitivity in prostate cancer cells by
incubation with genistein and estradiol. Radiation Oncology 3:19
Schubert A, Schulz H, Emons G, Gründker C (2008)
Expression of OPG and RANKL in HCC70 breast cancer cells and effects of GnRH
treatment on RANKL expression. Gynecological
Endocrinology 24(6):331-338
Gründker C, Günthert AR, Emons G (2008) Hormonal
Heterogeneity of Endometrial Cancer. In Innovative Endocrinology of
Cancer, eds. Berstein LM and Santen RJ, Landes Bioscience, Austin, Texas and
Springer, Berlin (Co-publisher), pp 166-188 (ISBN: 978-0-387-78817-3)
Hawighorst
T, Hussein F, Stein W, Gründker C, Emons G (2008) Anti-Angiogenese: Von der
präklinischen Forschung zur klinischen Anwendung. Geburtshilfe und Frauenheilkunde 68(4):397-403
Fister S, Schlotawa L, Günthert AR, Emons G, Gründker
C (2008) Increase of Doxorubicin-induced apoptosis after knock-down of GnRH
receptor expression in human endometrial, ovarian and breast cancer
cells. Gynecological Endocrinology 24(1):24-29
Girgert R, Gründker C, Emons G, Hanf V (2008)
Electromagnetic fields alter the expression of estrogen receptor cofactors in
breast cancer cells. Bioelectromagnetics 29(3):169-176
Schulten HJ, Wolf-Salgó J, Gründker C, Gunawan B,
Füzesi L (2008) Characterization of a newly established uterine carcinosarcoma
cell line featuring the sarcomatous phenotype of the tumor in vitro. International
Journal of Gynecological Cancer 28(2):339-344
Gründker
C, Fister S, Emons G (2007) GnRH Rezeptor-vermittelte Tumortherapie. Geburtshilfe
und Frauenheilkunde 67(12):1359-1363
Herrmann RM, Schwarten D, Fister S, Gründker C,
Rave-Fränk M, Nitsche M, Hille A, Thelen P, Schmidberger H, Christiansen H
(2007) No supra-additive effects of goserelin and radiotherapy on clonogenic
survival of prostate carcinoma cells in vitro. Radiation
Oncology 2:31
Hermann RM, Fest J, Christiansen M, Hille A,
Rave-Fränk M, Nitsche M, Gründker C, Viereck V, Jarry J, Schmidberger H (2007)
Radiosensitisation dependent on p53 function in bronchial carcinoma cells by
the isoflavone genistein and estradiol in vitro. Strahlentherapie und
Onkologie 183:195-202
Fister S, Günthert AR, Emons G, Gründker C (2007)
Gonadotropin-releasing hormone type II antagonists induce apoptotic cell death
in human endometrial and ovarian cancer cells in vitro and in
vivo. Cancer Research 67:1750-1756
Eicke N, Günthert AR, Emons G, Gründker C (2006)
GnRH-II agonist [D-Lys6]GnRH-II inhibits the EGF-induced mitogenic signal
transduction in human endometrial and ovarian cancer cells. International
Journal of Oncology 29:1223-1229
Gründker
C, Günthert AR, Emons G (2006) Zielzellspezifische Chemotherapie über den
GnRH-Rezeptor. Frauenarzt 47(7):590-592
Schneider F, Tomek W, Gründker C (2006)
Gonadotropin-releasing hormone (GnRH) and its natural analogues: A
review. Theriogenology 66:691-709
von Alten J, Fister S, Schulz H, Viereck V, Frosch KH,
Emons G, Gründker C (2006) GnRH analogs reduce invasiveness of human breast
cancer cells. Breast Cancer Research and
Treatment 100:13-21
Viereck
V, Gründker C, Frosch KH, Nisslein T, Hofbauer LC, Emons G (2006) Ein
isopropanolischer Extrakt der Traubensilberkerze (iCR) stimuliert die
Expression von Osteoprotegerin in primären humanen Osteoblasten. Journal für Menopause 13:18-21
Girgert R, Schimming H, Körner W, Gründker C, Hanf V
(2005) Induction of tamoxifen resistance in breast cancer cells by ELF
electromagnetic fields. Biochemical and Biophysical Research
Communication 336:1144-1149
Viereck V*, Gründker C*, Friess S, Frosch KH, Raddatz
D, Schoppet M, Nisslein T, Emons G, Hofbauer LC (2005) An isopropanolic extract
of black cohosh stimulates osteoprotegerin production by human
osteoblasts. Journal of Bone and Mineral Research 20:2036-2043 (*V.V.
and C.G. contributed equally to this work)
Viereck V, Gründker C, Blaschke S, Frosch KH, Schoppet
M, Emons G, Hofbauer LC (2005) Atorvastatin stimulates the production of
osteoprotegerin by human osteoblasts. Journal of Cellular
Biochemistry 96:1244-1253
Günthert AR, Gründker C, Olota A, Läsche J, Eicke N,
Emons G (2005) Analogs of gonadotropin-releasing hormone I (GnRH-I) and GnRH-II
inhibit EGF-induced signal transduction and resensitize resistant human breast
cancer cells to 4OH-tamoxifen. European Journal of
Endocrinology 153:613-625
Eicke N, Günthert AR, Viereck V, Siebold D, Béhé M,
Becker T, Emons G, Gründker C (2005) GnRH-II receptor-like antigenicity in
human in human placenta and in cancers of human reproductive
organs. European Journal of Endocrinology 153:605-612
Gründker C, Millar RP, Catt KJ, Naor Z, Leung PC,
Emons G (2005) Mechanisms of Action of GnRH. In GnRH Analogs in Human
Reproduction, ed. Lunenfeld B, Taylor & Francis, London, pp 1-33
Gründker C, Huschmand Nia A, Emons G (2005) GnRH
receptor-mediated gene therapy of gynecological cancers. Molecular Cancer
Therapeutics 4:225-231
Gründker C, Günthert AR, Hellriegel M, Emons G (2004)
Gonadotropin-releasing hormone (GnRH) inhibits estradiol-induced serum response
element (SRE) activation and c-fos expression in human endometrial, ovarian and
breast cancer cells. European Journal of Endocrinology 151: 619-628
Günthert AR, Gründker C, Bongertz T, Schlott T, Nagy
A, Schally AV, Emons G (2004) Internalisation of cytotoxic luteinizing
hormone-releasing hormone analog AN-152 induces multi drug resistance 1 (MDR-1)
-independent apoptosis in human endometrial and ovarian cancer cell
lines. American Journal of Obstetrics and Gynecology 191:1164-1172
Günthert AR, Gründker C, Bongertz T, Nagy A, Schally
AV, Emons G (2004) Induction of apoptosis by AN-152, a cytotoxic analog of
luteinizing hormone-releasing hormone (LHRH), in LHRH-R positive human breast
cancer cells is independent of multi drug resistance-1 (MDR-1)
system. Breast Cancer Research and Treatment 87:255-264
Gründker C, Schlotawa L, Viereck V, Eicke N, Horst A,
Kairies B, Emons G (2004) The antiproliferative effects of GnRH antagonist
Cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not
mediated through the GnRH type I (GnRH-I) receptor. European Journal of
Endocrinology 151:141-149
Günthert AR, Gründker C, Böttcher B, Höpker M, Nagy A,
Schally AV, Emons G (2004) Luteinizing hormone-releasing hormone (LHRH)
inhibits cytotoxic agent- and UV-light-induced but not CD95-mediated apoptosis
via activation of NFkB. Anticancer Research 24:1727-1732
Gründker C, Emons G (2003) Role of
gonadotropin-releasing hormone (GnRH) in ovarian cancer. Reproductive
Biology and Endocrinology 1:65
Emons G, Gründker C, Günthert AR, Westphalen S,
Kavanagh J, Verschraegen C (2003) GnRH antagonists in the treatment of
gynecological and breast cancers. Endocrine Related Cancer 10:291-299
Viereck V, Gründker C, Blaschke S, Niederkleine B,
Siggelkow H, Frosch KH, Raddatz D, Emons G, Hofbauer LC (2003) Raloxifene
concurrently stimulates osteoprotegerin and inhibits interleukin-6 production
by human trabecular osteoblasts. Journal of Clinical Endocrinology and
Metabolism 88:4206-4213
Emons
G, Gründker C, Hanf V (2002) Are estrogens carcinogens? Zentralblatt für Gynäkologie 124:559-565
Gründker C, Günthert AR, Westphalen S, Emons G (2002)
Biology of GnRH systems in human gynecological cancers. European Journal
of Endocrinology 146:1-14
Günthert AR*, Gründker C*, Hollmann K, Emons G (2002)
Luteinizing hormone-releasing hormone (LHRH) induces JunD-DNA binding and
extends cell cycle in human ovarian cancer cells. Biochemical and
Biophysical Research Communication 294:11-15 (*A.R.G. and C.G. contributed
equally to this work)
Gründker C, Völker P, Griesinger F, Ramaswamy A, Nagy
A, Schally AV, Emons G (2002) Antitumor effects of cytotoxic LHRH analog AN-152
on human endometrial and ovarian cancers xenografted into nude
mice. American Journal of Obstetrics and Gynecology 187:528-537
Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S,
Gründker C, Hofbauer LC (2002) Bisphosphonates pamidronate and zoledronic acid
stimulate osteoprotegerin production by primary human
osteoblasts. Biochemical and Biophysical Research
Communication 291:680-686
Gründker C, Günthert AR, Millar RP, Emons G (2002)
Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human
endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell
proliferation. Journal of Clinical Endocrinology and
Metabolism 87:1427-1430
Viereck V, Gründker C, Blaschke S, Siggelkow H, Emons
G, Hofbauer LC (2002) Phytoestrogen genistein stimulates the production of
osteoprotegerin by human trabecular osteoblasts. Journal of Cellular
Biochemistry 84:725-735
Völker P, Gründker C, Schmidt O, Schulz KD, Emons G
(2002) Expression of receptors for luteinizing hormone-releasing hormone in
human ovarian and endometrial cancers: frequency, autoregulation and
correlation with direct antiproliferative activity of LHRH
analogues. American Journal of Obstetrics and Gynecology 186:171-179
Randelzhofer
B, Engel U, Sammet I, Schauenburg H, Pauer U, Gründker C, Rüger U, Engel W,
Emons G (2001) Familiäres Mamma- und Ovarialkarzinom - Tumorrisiko-Sprechstunde
des Universitätsklinikums Göttingen. Niedersächsisches Ärzteblatt 74:33-37
Gründker C, Schlotawa L, Viereck V, Emons G (2001)
Protein kinase C (PKC)-independent stimulation of activator protein-1 (AP-1)
and c-Jun N-terminal kinase (JNK) activity in human endometrial cancer cells by
luteinizing hormone-releasing hormone (LHRH) agonist Triptorelin. European
Journal of Endocrinology 145:651-658
Gründker C, Völker P, Emons G (2001) Antiproliferative
signaling of LHRH in human endometrial and ovarian cancer cells through G-protein ai-mediated activation of phosphotyrosine
phosphatase. Endocrinology 142:2369-2380
Gründker C, Emons G (2001) Biology of GnRH systems in
cancer and human reproduction. In GnRH Analogues, The State of the Art
2001, ed. Lunenfeld B, Parthenon Publishing, Carnforth, pp 15-42
Gründker C, Emons G (2000) GnRH signal transduction in
gynecological cancers. Hormone Frontier in Gynecology 7:406-414
Gründker C (2000) Cytotoxic luteinizing
hormone-releasing hormone conjugates and its use in cancer
therapy. European Journal of Endocrinology 143:569-572
Westphalen S, Kotulla G, Kaiser F, Krauß W, Werning G,
Elsässer HP, Nagy A, Schulz KD, Gründker C, Schally AV, Emons G (2000) Receptor
mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in
human ovarian and endometrial cancer cell lines. International Journal of
Oncology 17:1063-106
Gründker C, Schulz K, Günthert AR, Emons G (2000)
Luteinizing hormone-releasing hormone induces nuclear factor kB-activation and
inhibits apoptosis in ovarian cancer cells. Journal of Clinical
Endocrinology and Metabolism 85:3815-3820
Gründker C, Völker P, Schulz KD, Emons G (2000)
Luteinizing hormone-releasing hormone (LHRH) agonist Triptorelin and antagonist
Cetrorelix inhibit EGF-induced c-fos expression in human gynecological
cancers. Gynecologic Oncology 78:194-202
Emons G, Weiß S, Ortmann O, Gründker C, Schulz KD
(2000) LHRH might act as a negative autocrine regulator of proliferation of
human ovarian cancer. European Journal of Endocrinology 142:665-670
Viereck V, Siggelkow H, Gründker C, Raddatz D, Hüfner
M, Emons G, Wuttke W (2000) Gene expression of steroid hormone receptors and
osteoblast phenotypic markers in HOS 58 cells. Advances in Obstetrics and
Gynecology 52:214-221
Gründker C, Emons G (1999) GnRH - Mechanisms of
Action. In GnRH Analogues, The State of the Art at the Millennium, ed. Lunenfeld
B, Parthenon Publishing, Carnforth, pp 7-29
Gründker C, Kirchner C (1996) Influence of uterine
growth factors on blastocyst expansion and trophoblast knob formation in the
rabbit. Early Pregnancy 2:264-270
Gründker C, Kirchner C (1996) Uterine fibroblast
growth factor-2 and embryonic fibroblast growth factor receptor-1 at the
beginning of gastrulation in the rabbit. Anatomy and
Embryology 194:169-175
Hrabé de Angelis M, Gründker C, Herrman BG, Kispert A,
Kirchner C (1995) Promotion of gastrulation by maternal growth factor in
cultured rabbit blastocysts. Cell and Tissue Research 282:147-154
Gründker C, Hrabé de Angelis M, Kirchner C (1994)
Chorionic gonadotropin-like proteins in the obplacental giant cells of the rabbit. Cell
and Tissue Research 278: 573-578
Gründker C, Hrabé de Angelis M, Kirchner C (1993)
Placental lactogen-like proteins in the rabbit placenta. Anatomy and
Embryology 188: 395-399
|
